Larry Turka, Rubius Therapeutics CSO
AACR22: Rubius touts new data for lead program, but shares routed as investors flee
Looking to build on its first cut of human data from last year, Rubius Therapeutics is touting new Phase I data from its lead cancer …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
